P. Sheffels

发表

Metabolic denitrosation of N-nitrosodimethylamine in vivo in the rat.

L. Keefer, C. S. Yang, B. Mico, 1990, Cancer research.

Binding of flexible ligands to proteins: Valproic acid and its interaction with cytochrome P450cam

T. Baillie, A. Rettie, G. Loew, 1993 .

Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

E. Kharasch, D. Whittington, N. Isoherranen, 2007, Clinical pharmacology and therapeutics.

Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine

E. Kharasch, D. Whittington, P. Sheffels, 2003, Clinical pharmacology and therapeutics.

METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES

E. Kharasch, O. Dale, P. Sheffels, 2005, Drug Metabolism and Disposition.

Metabolism of alfentanil by cytochrome P 4503 A ( CYP 3 A ) enzymes

E. Kharasch, O. Dale, P. Sheffels, 2004 .

Deuterium isotope effect on the toxicokinetics of monomethylamine in the rat.

L. Keefer, J. Hrabie, B. Mico, 1990, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5

E. Kharasch, K. Thummel, P. Sheffels, 2005, Anesthesiology.

CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.

T. Baillie, A. Rettie, K. Korzekwa, 1995, Biochemistry.

Disposition of nasal, intravenous, and oral methadone in healthy volunteers

E. Kharasch, O. Dale, P. Sheffels, 2002, Clinical pharmacology and therapeutics.

Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans.

Steven W. Martin, T. Baillie, M. Kerr, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans.

Steven W. Martin, T. Baillie, R. Levy, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-α-Acetylmethadol

P. Vicini, E. Kharasch, D. Whittington, 2005 .

Role of CYP2B6 in Stereoselective Human Methadone Metabolism

E. Kharasch, D. Whittington, K. Thummel, 2008, Anesthesiology.

New Insights into the Mechanism of Methoxyflurane Nephrotoxicity and Implications for Anesthetic Development (Part 1): Identification of the Nephrotoxic Metabolic Pathway

H. D. Liggitt, J. Schroeder, E. Kharasch, 2006, Anesthesiology.

Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First‐Pass CYP3A Activity

E. Kharasch, P. Sheffels, C. Hoffer, 2005, Journal of clinical pharmacology.

Synthetic applications of Group V metallacyclopropenes. Part 1. Group V metallacyclopropenes in synthesis. An efficient route to polyfunctional ring systems via the cocyclization of diynes with substituted monoacetylenes

T. Livinghouse, Andrew C. Williams, P. Sheffels, 1989 .

Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism

E. Kharasch, D. Whittington, R. Totah, 2007, Journal of Pharmacology and Experimental Therapeutics.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

E. Kharasch, D. Whittington, P. Sheffels, 2004, Clinical pharmacology and therapeutics.

Influence of Sevoflurane on the Metabolism and Renal Effects of Compound A in Rats

H. D. Liggitt, J. Schroeder, E. Kharasch, 2005, Anesthesiology.

Decomposition and quality control considerations in biological work with fecapentaene preparations.

L. Keefer, A. Streeter, P. Sheffels, 1989, Chemical Research in Toxicology.

Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.

H. D. Liggitt, J. Schroeder, E. Kharasch, 2004, Chemical research in toxicology.

Bioavailabilities of rectal and oral methadone in healthy subjects.

E. Kharasch, O. Dale, P. Sheffels, 2004, British journal of clinical pharmacology.

Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis

E. Kharasch, P. Sheffels, C. Hoffer, 2004, Clinical pharmacology and therapeutics.

Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry.

E. Kharasch, D. Whittington, P. Sheffels, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluation of First‐Pass Cytochrome P4503A (CYP3A) and P‐Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination

Evan D Kharasch, E. Kharasch, Christine Hoffer, 2005, Journal of clinical pharmacology.

Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first‐pass cytochrome P4503A activity

E. Kharasch, P. Sheffels, C. Hoffer, 2003, Clinical pharmacology and therapeutics.

Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

P. Vicini, E. Kharasch, D. Whittington, 2005, Clinical pharmacokinetics.